Latest ebit for VERO: $-38M, below the Healthcare sector average of $23B.
Get informed when a big investor buys or sells
+ FollowAs of Sep 30, 2025
Trailing 12 months ending Sep 30, 2025
As of the most recent data (September 2025), VERO shows a EBIT of $-38M. That compares with $-28M in the prior-year period — down 34.5% year over year. That is below the Healthcare sector average of $23B. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, VERO's EBIT is now $-38M (was $-28M) — a 34.5% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Venus Concept is outperforming or lagging.
The Healthcare sector average EBIT is about $23B. Venus Concept is at $-38M, which is lower that average. That is roughly 100.2% below the sector mean. Use the comparison chart on this page to see how VERO stacks up against individual peers as well.
Tracking VERO's ebit over time shows whether Venus Concept is scaling, shrinking, or reshaping that part of the business. The current reading is $-38M That compares with $-28M in the prior-year period — down 34.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this ebit page, Stockcircle has Venus Concept's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-38M) with ownership activity and broader fundamentals.